The Effectiveness of Montelukast on Atopic Dermatitis in Koreans
Information source: Soonchunhyang University Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Atopic Dermatitis
Intervention: Montelukast sodium (Drug); Placebo (Drug)
Phase: N/A
Status: Completed
Sponsored by: Pyun BokYang Official(s) and/or principal investigator(s): Bok Yang Pyun, M.D., PhD., Study Chair, Affiliation: Pediatric Allergy & Respiratory Center, Department of Pediatrics, Soonchunhyang University Hospital
Summary
The purpose of this study is to assess the clinical effectiveness of Montelukast in children
(2~6 years old) with atopic dermatitis and identify the pathophysiologic background of
Montelukast on the role of modulating the atopic dermatitis measured by urinary Leukotriene
4 (LTE4) and Eosinophil protein X(EDN).
Clinical Details
Official title: A Double Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Koreans
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Changes in SCORAD IndexChanges in Urinary LTE4 Changes in Urinary EDN
Detailed description:
Leukotriene B4 (LTB4) and the cysteinyl-leukotrienes LTC4, LTD4 and LTE4 are potent
proinflammatory mediators derived from arachidonic acid through the 5- lipoxygenase pathway.
They are secreted from eosinophils and other inflammatory cells such as mast cells and
macrophages. The primary action of leukotrienes includes contraction of human airway muscle,
chemotaxis, and increased vascular permeability, with secondary effects of inhibiting
allergen-induced early and late responses. Several in vivo and in vitro studies suggest a
role for cysteinyl leukotrienes in the pathogenesis of atopic dermatitis and there is a
rationale for the use of pharmacological agents to antagonize their effects in the treatment
of atopic dermatitis. Levels of LTE4 measured in urine (Urinary-LTE4) may be a useful
measure of whole-body cysteinyl-leukotriene production in vivo, because that LTE4 is a
stable urinary metabolite of LTC4 and LTD4. Urinary-LTE4 has been measured in individuals
with atopic dermatitis, but in small-scale studies, and the results are conflicting.
Eligibility
Minimum age: 2 Years.
Maximum age: 6 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- The ages of 2 to 6 years old, 54 children with moderate to severe atopic
dermatitis diagnosed by the criteria of Haniffin and Rajka were included in the
study.
- Volunteer children with moderate to severe atopic dermatitis were recruited from the
Pediatric Allergy and respiratory Center of the SoonChunHyang University Hospital
(Seoul, Korea). At the time of recruitment, written consent was obtained. The ethical
committee at the SoonChunHyang University Hospital approved the trial.
- Volunteers who agreed by their parents.
- The severity of their disease was assessed by modified SCORAD index.
Exclusion Criteria:
- Too severe atopic dermatitis defined as the sum of scores is 80 and above by
SCORAD index.
- A history of liver disease; allergy to montelukast or cross-reacting medication; use
of phenobarbital, phenytoin or rifampicin.
- Patients on systemic steroids, immune-suppression or Korean herbal medicine during
the previous 6 weeks.
Locations and Contacts
Pediatric Allergy & Respiratory Center, Department of Pediatrics, Soonchunhyang University Hospital, Seoul 140-743, Korea, Republic of
Additional Information
Starting date: August 2009
Last updated: August 15, 2012
|